With the absolute gold standard structure of this international study - I agree that this will be non issue. Also - clsn is patent strong. They have patents thru 2025 for their thermodox technology, in the US and Asia. Their liposomal technology is a drug delivery system - enhancing targeted delivery of already approved drugs - and they have a pipeline of known chemo agents fitted to this less toxic delivery method. Theirs is a much less risky platform than most biotechs.
Market Data 
Markets 
AI
